Neurological Features During COVID19

Encephalitis Clinical Trial

— NeuroSARS  

Official title:

Description of neurolOgical Involvement Observed During SARS COV2 Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04460599
• Other study ID #: Brain COVID
• Status: Recruiting
• Start date: March 8, 2020
• Est. completion date: September 30, 2020

Study information

• Verified date: July 2020
• Source: Centre d'Investigation Clinique et Technologique 805
• Contact: David Orlikowski, MD PhD
• Phone: 0147107777
• Email: david.orlikowski[@]aphp.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Description of the neurological impairment: clinico-radiological and electrophysilogical correlations

Description:

Describe short and long term clinical radiological and electrophysilogical presentations of neurological damage central and peripheral SARS COV2 infection Describe the association between neurological, respiratory and dysautonomic Determine the prognosis of neurological damages to short and long term.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 30, 2020
• Est. primary completion date: July 30, 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PCR SARS COV2 positive or CT Scan

• Central neurological signs such as confusion, epilepsy, abnormal movement, pyramidal signs, motor or sensory deficit, involvement of cranial pairs (such as anomie or ageusia) or peripheral.

• Dysautonomic signs such as hypotension or hypertension, bradycardia or tachycardia, hypothermia, SIADH not explained by therapy or a pathology other than SARS COV 2 infection

Exclusion Criteria:

• Contraindication to performing an MRI scan

• Minor

• Pregnant woman

• No follow-up possible at 6 months

Related Conditions & MeSH terms

• Encephalitis

Intervention

Other:
• Observation
Observation of recorded neurological signs

Locations

Country	Name	City	State
France	Hopital Raymond Poincare	Garches

Sponsors (1)

Lead Sponsor	Collaborator
Centre d'Investigation Clinique et Technologique 805

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary	incidence of objective neurological damage	6 months
Secondary	Secondary	incidence of clinical neurological damage incidence of radiological neurological damage incidence of neurophysiological neurological damage	6 months